Andreas W Berger
Overview
Explore the profile of Andreas W Berger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
225
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nitschke C, Tolle M, Walter P, Meissner K, Goetz M, Kropidlowski J, et al.
Mol Oncol
. 2024 Sep;
PMID: 39219164
Intraductal papillary mucinous neoplasms (IPMNs) are potential precursor lesions of pancreatic cancer. We assessed the efficacy of screening for KRAS proto-oncogene, GTPase (KRAS), and GNAS complex locus (GNAS) mutations in...
2.
Seufferlein T, Lausser L, Stein A, Arnold D, Prager G, Kasper-Virchow S, et al.
PLoS One
. 2024 Jun;
19(6):e0304324.
PMID: 38875244
Background: Anti-vascular endothelial growth factor (VEGF) monoclonal antibodies (mAbs) are widely used for tumor treatment, including metastatic colorectal cancer (mCRC). So far, there are no biomarkers that reliably predict resistance...
3.
Ettrich T, Modest D, Sinn M, Striefler J, Opitz B, Goetze T, et al.
J Clin Oncol
. 2024 Jun;
42(26):3094-3104.
PMID: 38843469
Purpose: First-line therapy options in advanced cholangiocarcinoma (CCA) are based on the ABC-02 trial regimen (gemcitabine/cisplatin [G/C]). The NIFE trial examined nanoliposomal irinotecan/fluorouracil/leucovorin (nal-IRI/FU/LV) as alternative first-line therapy in advanced...
4.
Sappok T, Kowalski C, Zenker M, Weissinger F, Berger A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
. 2024 Feb;
67(3):362-369.
PMID: 38334785
Intellectual disability has a prevalence rate of approximately 1% of the population; in Germany, this is around 0.5-1 million people. The life expectancy of this group of people is reduced,...
5.
Seufferlein T, Ettrich T, Menzler S, Messmann H, Kleber G, Zipprich A, et al.
Am J Gastroenterol
. 2022 Feb;
117(6):884-894.
PMID: 35213393
Introduction: Preclinical, epidemiological, and small clinical studies suggest that green tea extract (GTE) and its major active component epigallocatechingallate (EGCG) exhibit antineoplastic effects in the colorectum. Methods: A randomized, double-blind...
6.
Ettrich T, Perkhofer L, Decker T, Hofheinz R, Heinemann V, Hoffmann T, et al.
Int J Cancer
. 2020 Sep;
148(6):1428-1437.
PMID: 32930387
Nintedanib is a triple angiokinase inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-3 and platelet-derived growth factor receptor-a/-b. Thereby, it targets angiogenic escape mechanisms. The...
7.
Berger A, Schwerdel D, Reinacher-Schick A, Uhl W, Algul H, Friess H, et al.
Theranostics
. 2019 Mar;
9(5):1280-1287.
PMID: 30867830
The most frequent malignancy of the pancreas is the pancreatic ductal adenocarcinoma (PDAC). Despite many efforts PDAC has still a dismal prognosis. Biomarkers for early disease stage diagnosis as a...
8.
Ettrich T, Berger A, Perkhofer L, Daum S, Konig A, Dickhut A, et al.
BMC Cancer
. 2018 Dec;
18(1):1298.
PMID: 30594153
Background: Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus, evaluation of perioperative chemotherapy in resectable pancreatic...
9.
Berger A, Raedler K, Langner C, Ludwig L, Dikopoulos N, Becker K, et al.
United European Gastroenterol J
. 2018 Mar;
6(2):290-299.
PMID: 29511559
Background And Objective: Current surveillance strategies for colorectal cancer following polypectomy are determined by endoscopic and histopathological factors. Such a distinction has been challenged. The present study was designed to...
10.
Berger A, Schwerdel D, Ettrich T, Hann A, Schmidt S, Kleger A, et al.
Oncotarget
. 2018 Feb;
9(2):2076-2085.
PMID: 29416754
Purpose: Precision medicine in pancreatic ductal adenocarcinoma (PDAC) could be substantially supported by tools that allow to establish and monitor the molecular setup of the tumor. In particular, noninvasive approaches...